A5053467199- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Cancer therapeutics and mechanisms
- Synthesis and Biological Evaluation
- Neuroblastoma Research and Treatments
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Click Chemistry and Applications
- Immune Cell Function and Interaction
- DNA Repair Mechanisms
- Cancer Research and Treatments
- Fungal and yeast genetics research
- Lung Cancer Treatments and Mutations
- Biotin and Related Studies
- Acute Lymphoblastic Leukemia research
- Virus-based gene therapy research
- Lung Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Toxin Mechanisms and Immunotoxins
- Retinoids in leukemia and cellular processes
Southern Medical University
2025
Fujian Medical University
2021-2024
University of South China
2024
Fred Hutch Cancer Center
2012-2023
Mayo Clinic
2021
WinnMed
2021
University of Washington
1990-2017
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2006-2011
Cancer Research Center
2006-2011
University Hospital of Lausanne
2011
Abstract We have targeted CD22 as a novel tumor-associated Ag for recognition by human CTL genetically modified to express chimeric TCR (cTCR) recognizing this surface molecule. CD22-specific cTCR targeting different epitopes of the molecule promoted efficient lysis target cells expressing high levels with maximum lytic potential that appeared decrease distance epitope from cell membrane increased. Targeting membrane-distal cTCR+ revealed defects in both degranulation and granule targeting....
We previously demonstrated the feasibility of generating therapeutic numbers cytotoxic T lymphocyte (CTL) clones expressing a CD20-specific scFvFc:CD3zeta chimeric cell receptor (cTCR), making them specifically for CD20+ B lymphoma cells. However, process and expanding he CTL was laborious, expressed cTCR at low surface density, they exhibited suboptimal proliferation cytotoxicity. To improve performance CTLs in vitro vivo, we engineered "second-generation'' plasmid constructs containing...
Modification of T cells with chimeric antigen receptors (CAR) has emerged as a promising treatment modality for human malignancies. Integration co-stimulatory domains into CARs can augment the activation and function genetically targeted against tumors. However, potential insertional mutagenesis toxicities due to infused have made development safe methods removing transferred an important consideration. We modified lentiviral vector express CD20-CAR containing both CD28 CD137 domains,...
To investigate the safety and feasibility of combining neoadjuvant sintilimab (Innovent Biologics, Suzhou, China) chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC).The study was an investigator-initiated, open-label, non-randomized, single-arm, single-center phase 2 trial. Patients aged between 18 to 75 years with ESCC were eligible immunochemotherapy (nICT). The nICT included cisplatin (60 mg/m2) on day 1, albumin-bound paclitaxel (125 days 1 8, (200 mg) each...
CDK2 and CDK9 play pivotal roles in cell cycle progression gene transcription, respectively, making them promising targets for cancer treatment. Herein, we discovered a series of N4-(substituted thiazol-2-yl)-N2-(4-substituted phenyl)pyrimidine-2,4-diamines as highly potent CDK2/9 dual inhibitors. Especially, compound 20a significantly inhibited (IC50 = 0.004 μM) 0.009 μM), achieving 1000- 2800-fold improvement over lead 11, demonstrating broad antitumor efficacy. Mechanistic studies...
We have earlier shown that attenuated measles virus (MV) has therapeutic potential as a replicating oncolytic in models of non-Hodgkin's lymphoma (NHL). In the current study, we investigated whether could obtain MVs capable entering CD20+ target cells through an interaction between single-chain (scFv) anti-CD20 antibody and CD20 antigen, considerable clinical relevance NHL. replaced H envelope glycoprotein MV by H-scFv fusion protein with without protease-cleavable linker. Biochemical...
The vast majority of patients with plasma cell neoplasms die progressive disease despite high response rates to novel agents. Malignant cells are very radiosensitive, but the potential role radioimmunotherapy (RIT) in management plasmacytomas and multiple myeloma has undergone only limited evaluation. Furthermore, CD38 not been explored as a RIT target its uniform expression on malignant cells. In this report, both conventional (directly radiolabeled antibody) streptavidin-biotin pretargeted...
Streptavidin provides an effective receptor for biotinylated tumoricidal molecules, including radionuclides, when conjugated to antitumor antibody and administered systemically. Ideally, one would like administer this bacterial protein patients repeatedly, so as maximize the effect without eliciting immune response. Therefore, we attempted reduce antigenicity of streptavidin by mutating surface residues capable forming high energy ionic or hydrophobic interactions. A crystallographic image...
Acute myelogenous leukemia (AML) currently kills the majority of afflicted patients despite combination chemotherapy and hematopoietic cell transplantation (HCT). Our group has documented promise radiolabeled anti-CD45 monoclonal antibodies (Ab) administered in setting allogeneic HCT for AML, but toxicity remains high, cure rates are only 25% to 30% relapsed AML. We now show superiority pretargeted radioimmunotherapy (PRIT) compared with conventional using a recombinant tetravalent...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTSynthesis of 3-fluorodiaminopimelic acid isomers as inhibitors diaminopimelate epimerase: stereocontrolled enzymatic elimination hydrogen fluorideMichael H. Gelb, Yukang Lin, Michael A. Pickard, Yonghong Song, and John C. VederasCite this: J. Am. Chem. Soc. 1990, 112, 12, 4932–4942Publication Date (Print):June 1, 1990Publication History Published online1 May 2002Published inissue 1 June...
Purpose Pretargeted radioimmunotherapy (PRIT) is a multi-step method of selectively delivering high doses radiotherapy to tumor cells while minimizing exposure surrounding tissues. Yttrium-90 (90Y) and lutetium-177 (177Lu) are two the most promising beta-particle emitting radionuclides used for radioimmunotherapy, which despite having similar chemistries differ distinctly in terms radiophysical features. These differences may have important consequences absorbed dose tumors normal organs....
Abstract Despite the promise of radioimmunotherapy using anti-CD20 antibodies (Ab) for treatment relapsed patients with indolent non-Hodgkin lymphoma (NHL), most treated conventional doses 131I-tositumomab or 90Y-ibritumomab eventually relapse. We did comparative assessments targeting CD20, CD22, and HLA-DR on human Ramos, Raji, FL-18 xenografts in athymic mice to assess potential improving efficacy by other NHL cell surface antigens. Results biodistribution studies showed significant...
Streptavidin (SA)-biotin pretargeted radioimmunotherapy (PRIT) that targets CD20 in non-Hodgkin lymphoma (NHL) exhibits remarkable efficacy model systems, but SA immunogenicity and interference by endogenous biotin may complicate clinical translation of this approach. In study, we engineered a bispecific fusion protein (FP) evades the limitations imposed system. Briefly, one arm FP was an anti-human antibody (2H7), with other anti-chelated radiometal trap for radiolabeled ligand...